RECOVER-Autonomic: Ivabradine Alone Did Not Improve Orthostatic Intolerance in Post-COVID POTS, But May Have Additional Benefit
Key Points: Postural orthostatic tachycardia syndrome (POTS) is a complex, multisystem disorder characterized by orthostatic intolerance and excessive tachycardia... Read more.
SPIRIT-HF Trial: No Significant Benefit of Spironolactone in HFpEF or HFmrEF, With Possible Signal of Harm
Key Points: Heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF) contribute substantially to the... Read more.
DAPT-MVD: Extended DAPT reduces MACCE in patients with multi-vessel disease after DES
Key Points: The optimal duration and choice of dual antiplatelet therapy (DAPT) after one year for patients with multivessel disease who undergo percutaneous coronary... Read more.
BETTER-BP: Offering Cash Incentives Improves Anti-Hypertensive Medication Adherence, But Not Blood Pressure Control
Key Points: Adherence to antihypertensive medications remains a persistent challenge in clinical practice. The BETTER-BP trial randomized participants with poorly... Read more.
OCEAN: Ongoing Anticoagulation May Not be Necessary After 1-year Post Successful AF Ablation
Key Points: Atrial fibrillation (AF) increases the risk of stroke, and long-term oral anticoagulation is generally recommended for patients with atrial fibrillation... Read more.
VESALIUS-CV: PCSK9-Inhibitor Evolocumab Reduces MACE for Primary Prevention
Key Points: PCSK9-inhibitors – including evolocumab – are highly effective LDL-C–lowering medications that reduce major adverse cardiovascular events (MACE)... Read more.
DR10624, a First-in-Class FGF21/GLUCAGON/GLP-1 Receptor Triple Agonist, Significantly REDUCED Triglycerides, Lipids, and Liver Fat in Patients with Severe HYPERTRIGLYCERIDEMIA
Key Points: DR10624 is a first-in-class triple agonist of the FGF21, glucagon, and GLP-1 receptors, designed to improve metabolic parameters in patients with severe... Read more.
NEWTON-CABG: Evolocumab Did Not Improve Vein Graft Patency After CABG
Key Points: Saphenous vein graft (SVG) failure is common after coronary artery bypass grafting (CABG), with an occlusion rates of 20% within the first year after... Read more.
Essence-TIMI 73b: Olezarsen Safely and Effectively Reduces Triglycerides in Patients With Moderate Hypertriglyceridemia and High CV Risk
Key Points: Olezarsen, an anti-sense oligonucleotide targeting APOC3 mRNA, is approved to lower triglycerides (TG) in adults with rare familial chylomicronemia,... Read more.
VICTOR: Vericiguat Did Not Meet Primary Endpoint But Reduced CV Death in Stable, Ambulatory HFrEF
Key Points: The VICOTRIA trial previously demonstrated that vericiguat reduced the risk of heart failure (HF) hospitalization or cardiovascular (CV) death in patients... Read more.